Penumbra's newest stroke intervention platform has been on the market only briefly, and it is already the subject of a five-patent infringement suit. On August 19, 2026, Incuvate, LLC sued Penumbra, Inc. in the Northern District of California (No. 4:26-cv-08658, Judge P. Casey Pitts), alleging that the THUNDERBOLT computer assisted vacuum thrombectomy system willfully infringes five Incuvate patents. Bird Marella (Ekwan Rhow, Timothy Yoo, and Richard Jung) signed the complaint. The case is worth watching for what it says about how sophisticated patent families are built and enforced, and for the counterattack it is likely to draw.
The technology, in plain English
Thrombectomy is the removal of blood clots through a catheter, often in acute stroke patients. Incuvate's patents, each titled "Aspiration monitoring system and method," describe systems that put a pressure sensor and a microprocessor between the catheter and the vacuum source. By comparing real-time pressure changes against stored thresholds, the system tells the physician, through lights and sounds, whether the catheter tip is ingesting clot, sitting in free-flowing blood, or clogged, and can automatically switch between continuous and modulated suction. The complaint alleges that Penumbra's THUNDERBOLT CAVT platform, marketed as computer assisted vacuum thrombectomy with algorithms that detect clot and modulate vacuum flow, uses exactly this architecture in the Penumbra ENGINE, THUNDERBOLT tubing and module, and RED Reperfusion Catheters: RED 62, RED 68, RED 72, RED 72 Silver Label, and RED 72 Silver Label with SENDit. The complaint also attaches Penumbra's U.S. Patent 12,667,376, issued June 30, 2026, and quotes it as describing THUNDERBOLT's windowed pressure-differential algorithms.
The continuation-chain story
All five asserted patents descend from one provisional application filed April 8, 2014: 9,248,221 (exemplary claim 5), 9,895,473 (claim 1), 10,603,415 (claim 1, a method), 11,678,896 (claim 1), and 12,539,127 (claim 11), with patents issuing in 2016, 2018, 2020, 2023, and, most recently, February 3, 2026, about six months before this complaint. The '415 count is induced-only: Incuvate says clinicians perform the method steps. Willfulness is pleaded on all five counts. The complaint emphasizes that THUNDERBOLT is "newly cleared and launched." Reading between the lines, this looks like disciplined continuation practice: keep the family alive at the Patent Office, watch the market develop, and prosecute claims that track where competitors are heading. That is lawful and common among well-advised patent owners, and it is exactly why defendants respond predictably. Expect Penumbra to test whether the newest claims are fully supported by the original 2014-era disclosure, through written description and priority challenges, and to argue that any claim scope added with THUNDERBOLT in view cannot reach back to the early filing date.
The venue choice
Incuvate sued Penumbra at home. Penumbra is headquartered in Alameda, which makes venue in the Northern District of California essentially unchallengeable under the patent venue statute after TC Heartland. Plaintiffs with forum flexibility often prefer faster, more plaintiff-tested districts, so filing in the defendant's backyard reads as a venue-proofing decision, and perhaps a confident one. The tradeoff is a district that historically takes longer than the plaintiff-tested patent venues, and that often stays a case while the Patent Office reviews the patents. That is a venue-culture observation, not a finding in this complaint.
The likely counterattack
Penumbra is not new to post-grant practice in this space. In IPR2021-01466, Paper 34 (PTAB Mar. 10, 2023), later designated precedential in part, Penumbra obtained a final written decision holding claims 1-18 of RapidPulse's U.S. Patent 10,531,883 unpatentable. The Federal Circuit affirmed by Rule 36 in RapidPulse, Inc. v. Penumbra, Inc., No. 2024-1130 (Oct. 14, 2025). The probabilistic call here is that Penumbra petitions for IPR against several members of the Incuvate family within the one-year statutory window and pairs those petitions with a motion to stay the district court case. A Section 101 motion looks less promising given the hardware-tied claims, so the merits fight in court will likely center on claim construction of the pressure threshold and differential limitations, noninfringement based on how THUNDERBOLT's algorithms actually operate, and invalidity.
The stakes and the realistic endgame
The prayer is damages (lost profits or a reasonable royalty), enhanced damages under section 284, a permanent injunction or an ongoing royalty, fees under section 285, and a jury. There is no preliminary-injunction request. Notice allegations include a May 2016 in-person meeting under NDA, a May 28, 2026 letter to William Yee (Senior Director of IP Strategy), and an August 7, 2026 supplemental letter naming THUNDERBOLT. Penumbra announced FDA clearance of THUNDERBOLT on June 11, 2026. The complaint describes Incuvate as a medical device incubator and developer. It does not plead that Incuvate sells a competing thrombectomy system, so any irreparable-harm showing under eBay remains untested. If the patents hold up, the more common endgame in that posture is a royalty on THUNDERBOLT sales, with willfulness preserving the threat of enhanced damages as settlement leverage. That is a probabilistic read, not a prediction of the outcome.
What to watch next
Penumbra's responsive pleading this fall (an answer, or an early motion); the initial case management conference and claim construction schedule; and the PTAB docket over the coming year, where the real validity fight may land. If IPR petitions arrive, watch whether the newest patent, the one issued in February 2026, is challenged on different grounds than its older siblings.